Other reported the similar result that anti-PD-1 antibodies achieved better efficacy compared with anti-PD-L1 antibody as monotherapy in patients with pre-treated NSCLC (Almutairi et al., 2019). The gene discussed is CD274; the disease is non-small cell lung carcinoma.